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Abstract
Background: Homoarginine is an amino acid derivative mainly synthesized in the kidney. It is suggested to increase nitric
oxide availability, enhance endothelial function and to protect against cardiovascular diseases. We aimed to investigate the
relation between homoarginine, kidney function and progression of chronic kidney disease (CKD).
Methods: We measured plasma homoarginine concentrations in baseline samples of the Mild to Moderate Kidney Disease
(MMKD) Study, a prospective cohort study of 227 patients with CKD in Europe. Homoarginine concentrations were available
in 182 of the baseline samples and in 139 of the prospectively-followed patients. We correlated homoarginine
concentrations to parameters of kidney function. The association between homoarginine and progression of CKD was
assessed during a follow-up of up to seven years (median 4.45 years, interquartile range 2.54–5.19) using Cox regression
analysis. Progression of CKD was defined as doubling of baseline serum creatinine and/or end-stage renal disease.
Results: Study participants were at baseline on average 47613 years old and 65% were male. Mean6standard deviation of
homoarginine concentrations were 2.561.1 mmol/L and concentrations were incrementally lower at lower levels of GFR
with mean concentrations of 2.9061.02 mmol/L (GFR.90 ml/min), 2.6461.06 mmol/L (GFR 60–90 ml/min), 2.5261.24 mmol/
L (GFR 30–60 ml/min) and 2.0560.78 mmol/L (GFR,30 ml/min), respectively (p = 0.002). The age- and sex-adjusted risk to
reach the renal endpoint was significantly higher by 62% with each decrease by one standard deviation (1.1 mmol/L) of
homoarginine (HR 1.62, 95% CI 1.16–2.27, p = 0.005). This association was independent of proteinuria (HR 1.56, 95% CI 1.11–
2.20, p = 0.01), and was slightly attenuated when adjusting for GFR (HR 1.40 (95% CI 0.98–1.98, p = 0.06).
Conclusions: Homoarginine concentrations are directly correlated with kidney function and are significantly associated with
the progression of CKD. Low homoarginine concentrations might be an early indicator of kidney failure and a potential
target for the prevention of disease progression which needs further investigations.
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Introduction
Chronic kidney disease (CKD) represents a major public health
problem with an increasing prevalence as well as an increase in the
incidence rate of end-stage renal disease [1,2]. The costs of
treatment put an enormous burden on health care resources since
renal replacement therapy represents one of the most expensive
chronic therapies. Importantly, CKD per se has been shown to be
a strong risk factor for cardiovascular morbidity and mortality [3].
Patients with a moderately impaired kidney function already have
a high risk to develop cardiovascular complications [4]. Cardio-
vascular risk further increases with the decline in kidney function,
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and the majority of CKD patients die from cardiac and vascular
events before reaching end-stage renal disease. Prevention of
disease progression and associated complications therefore is
highly important including the treatment of renal risk factors.
Homoarginine is a cationic amino acid, which is derived from
lysine and mainly synthesized in the kidney by transaminidation of
its precursor [5,6]. Genetic studies identified polymorphisms of the
L-arginine:glycine amidinotransferase (AGAT), which is the main
enzyme responsible for homoarginine formation, to be signifi-
cantly associated with kidney function in humans [7,8]. Studies
have shown that homoarginine may have beneficial effects on
renal risk factors such as hypertension and glycemia. In an animal
study, the administration of L-homoarginine increased urinary
excretion of nitrate, the degradation product of NO, and reduced
blood pressure in salt-sensitive hypertensive rats [9]. Homoargi-
nine was found to stimulate insulin secretion [10,11] which is
relevant for the glycemic control to preserve kidney function [12].
Interestingly, disturbances in calcium-phosphate metabolism,
which are known to contribute to the progression of CKD [13],
are positively affected by homoarginine. Homoarginine was
suggested to inhibit bone alkaline phosphatase [14,15], negatively
correlate to beta-crosslaps and osteocalcin and decrease the risk of
fractures [16,17]. Importantly, homoarginine serves as a precursor
of NO [18–21] and inhibits arginase. Thus, homoarginine may
increase the availability of NO and impede or ameliorate
endothelial dysfunction [9,18–22], which is crucial to prevent
progression of CKD.
Therefore, we reasoned that a lack of homoarginine contributes
to CKD progression: we hypothesized that a low blood
concentration of homoarginine associates with a decline in kidney
function and shorter time to end-stage renal disease. We therefore
analyzed data of the Mild to Moderate Kidney Disease Study
(MMKD Study), which is a prospective cohort study of 227
patients with primary nondiabetic CKD in Europe [23,24].
Methods
Baseline Investigation
The methodology of the MMKD Study has previously been
reported in detail [23,24]. Briefly, the MMKD Study is a
prospective cohort study including 227 white patients aged
between 18 and 65 years with nondiabetic CKD and various
degrees of kidney impairment. The patients were recruited from 8
nephrology departments in Germany, Austria, and South Tyrol
(Italy) as previously described [25]. The patients had stable kidney
function for at least 3 months before inclusion into the study.
Exclusion criteria were serum creatinine .6 mg/dL (531 mmol/
L), diabetes mellitus of any type, malignancy, liver, thyroid, or
infectious diseases, nephrotic syndrome (defined as daily protein-
uria .3.5 g/1.73 m2), organ transplantation, immunosuppressive
treatment, allergy to ionic contrast media, treatment with fish oil
or erythropoietin and pregnancy.
To avoid interobserver differences, all patients were recruited by
a single investigator who visited all participating centers.
Information on age, gender, smoking habits, comorbidities and
antihypertensive treatment at baseline was recorded by patient
interview and confirmed by checking patient records. A clinical
examination completed the procedure. Body mass index (BMI)
was calculated as weight (kg) divided by height (m) squared. Blood
pressure was measured in sitting position. Hypertension was
defined as BP.140/90 mmHg and/or the use of antihypertensive
medication.
Ethics Statement
The study was approved by the Institutional Ethic Committee
of the University of Innsbruck, and all participants gave their
informed consent before inclusion in the study.
Prospective Follow-Up and Outcome Assessment
Patients were followed prospectively until the primary study
endpoint or the end of the follow-up period was reached. The
primary endpoint was defined as doubling of baseline serum
creatinine and/or terminal renal failure necessitating renal
replacement therapy (dialysis therapy or kidney transplantation).
A total of 177 (78%) patients from the baseline cohort of 227
patients could be followed prospectively over a period of up to 7
years. Patients received regular follow-up care in the outpatient
ward and the endpoint was assessed by medical record abstraction.
Patients who were lost to follow-up (n= 50) had at baseline a
significantly better renal function than patients who were not lost
to follow-up (i.e., a higher mean GFR [91644 versus 64639 ml/
min per 1.73 m2; P,0.01]). However, both groups did not differ
significantly with respect to age and gender. Patients who were lost
to follow-up had moved away or were not referred by their
physicians for follow-up visits in the renal units.
Homoarginine and GFR Measurement
Homoarginine was measured in plasma samples taken at
baseline and stored at 280uC, using a reverse-phase HPLC
method [26,27]. Within-day coefficients of variation (CV) were
4.7% (for a control sample with 1.21 mmol/L) and 2.2%
(3.53 mmol/L), and between-day CV were 7.9% (1.25 mmol/L)
and 6.8% (3.66 mmol/L), respectively. GFR was assessed in all
patients using the iohexol clearance technique as described in
detail elsewhere [28].
Statistical Analysis
Continuous variables were compared between various groups
using unpaired t tests or the nonparametric Wilcoxon rank sum
test in case of non-normally distributed variables. Continuous
variables across the stages of CKD were analyzed using one-way
ANOVA or Kruskal-Wallis test where appropriate. Dichotomized
variables were compared using Pearson x2-test. We explored the
correlation of homoarginine with other parameters using either
Pearson or Spearman correlation analysis depending on the
distribution of the analyzed variables. Cox regression analyses
were applied to calculate hazard ratios (HRs) and corresponding
95% confidence intervals per one standard deviation change of
homoarginine for the progression to renal endpoints adjusted for
age, sex, and other risk predictors of disease progression. The
calculated Cox regression models did not violate the proportional
hazards assumption. Moreover, using non-linear splines, models
did not depart from linearity. A two-sided p-value,0.05 was
considered statistically significant. Analyses were performed using
SPSS for Windows version 18.0 and R 2.14.2.
Results
Patient Characteristics
Of all 227 non-nephrotic patients included into the MMKD
study, 182 patients with biological material available had a
homoarginine measurement in the baseline samples. The mean
homoarginine concentration was 2.5761.09 mmol/L. Character-
istics of patients with and without homoarginine values were not
significantly different (Table S1). The baseline clinical character-
istics and laboratory data of these patients are reported in Table 1.
Overall, patients had a mean age of 46613 years and 67% were
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male. Of the 182 patients, 59 patients had CKD stage 1 with a
GFR $90 ml/min, 35 patients had stage 2 with a GFR $60–
89 ml/min, 51 patients had stage 3 with a GFR $30–59 ml/min
and 37 patients had CKD stage 4 or 5 with a GFR,30 ml/min.
Homoarginine concentrations were incrementally lower at lower
levels of GFR with mean concentrations of 2.9061.02 mmol/L
(stage 1), 2.6461.06 mmol/L (stage 2), 2.5261.24 mmol/L (in
stage 3) and 2.0560.78 (stage 4–5), respectively. The differences in
mean homoarginine concentrations across the stages of CKD were
highly significant (p = 0.002). By correlation analyses, homoargi-
nine concentrations were significantly related to GFR (r = 0.25,
p = 0.001), proteinuria (r =20.21, p = 0.005) and creatinine
(r =20.31, p,0.001). Homoarginine concentrations did not
correlate with age (r =20.06, p = 0.44), but slightly with BMI
(r = 0.17, p = 0.02) and albumin (r = 0.15, p = 0.05), respectively.
Patients with a lower GFR were older, had a higher BMI and
lower serum albumin concentrations than those with a higher
GFR.
Homoarginine and Progression of CKD
Of the 177 patients in the MMKD study who could be followed
prospectively until the end of the study or occurrence of the
primary renal endpoint, a total of 139 patients had a homo-
arginine measurement available at baseline. Patients with and
without homoarginine measurements and follow-up time were
very similar in their clinical characteristics (Table S2). The median
follow-up time was 4.45 years with an interquartile range of 2.54–
5.19 years. Of those 139 patients, 56 patients (40.3%) experienced
a renal disease progression (doubling of baseline serum creatinine
and/or terminal renal failure necessitating renal replacement
therapy). Homoarginine concentrations were significantly lower in
these patients as compared to those without kidney disease
progression (2.1960.93 versus 2.7161.13 mmol/L, respectively,
p = 0.005). The further characteristics of the patients with and
without kidney disease progression are presented in Table 2.
We performed Cox regression analyses considering the time of
reaching the kidney endpoint (Table 3). The age and sex-adjusted
hazard ratio to suffer a kidney endpoint was significantly higher by
62% with each decrease of one standard deviation (1.1 mmol/L) of
homoarginine (HR 1.62, 95% CI 1.16–2.27, p= 0.005). Further
adjustment for proteinuria did not change the results (HR 1.56,
95% CI 1.11–2.20, p= 0.01). Additional adjustment for measured
GFR slightly attenuated the association, resulting in a borderline
significant hazard ratio of 1.40 (95% CI 0.98–1.98, p = 0.06).
In additional analyses we investigated the role of nutritional
status in the association of homoarginine with the progression of
CKD. Neither BMI nor albumin was associated with the
progression of kidney disease and the relationship of homoarginine
with CKD progression was still significant after adjustments for
albumin and BMI (HR 1.44, 95% CI 1.01–2.05, p= 0.045).
Discussion
This is the first study that describes plasma homoarginine
concentrations in patients with primary non-diabetic chronic
kidney disease not requiring dialysis. The main findings of this
study are that 1) circulating homoarginine concentrations in CKD
patients are significantly lower with lower GFR; 2) homoarginine
concentrations were substantially lower in patients with kidney
disease progression as compared to those without progression; 3)
circulating homoarginine concentrations are inversely associated
with the risk to reach a kidney endpoint, independently of age, sex
and proteinuria. This association was slightly attenuated after
additional adjustment for GFR (p= 0.06).
Table 1. Baseline clinical and laboratory data of 182 patients with non-diabetic chronic kidney disease stratified by GFR stages
according to K/DOQI guidelines.
GFR (mL/min/1.73 m2)
$90 60–89 30–59 ,30
Variable all patients (n =59) (n=35) (n =51) (n=37) p-value
Sex: males/females, n (%) 122/60 41/18 24/11 35/16 22/15 0.75
(67.0/33.0) (69.5/30.5) (68.6/31.4) (68.6/31.4) (59.5/40.5)
Age (years) 45.8612.8 40.5613.4 45.8612.3 45.9611.7 54.269.0 ,0.001
BMI (kg/m2) 25.2163.6 24.263.3 25.863.6 25.163.1 26.264.3 0.04
Current smokers, n (%) 36 (20) 15 (25) 8 (23) 6 (12) 7 (19) 0.73
Systolic blood pressure (mmHg) 137621 135622 138625 138618 138619 0.82
Diastolic blood pressure (mmHg) 86613 83613 86613 86613 88614 0.40
Serum albumin (g/dL) 4.660.4 4.760.4 4.460.6 4.660.4 4.560.4 0.005
Proteinuria (g/24 h/1.73 m2) 0.9060.90 0.5660.65 1.1061.11 1.0160.95 1.1060.81 0.001
(0.18;0.55;1.26) (0.12;.0.35;0.73) (0.17;0.60;1.80) (0.22;0.55;1.78) (0.54;0.95;1.52)
GFR (mL/min/1.73 m2) 69643 120629 7369 4567 1968 ,0.001
(38;63;96) (96;111;134) (65;70;81) (40;44;50) (12;18;27)
Creatinine - standardized 1796113 89621 136649 202672 3346115 ,0.001
measurement (mmol/L) (96;135;231) (73;84;107) (108;127;142) (154;188;237) 253;319;422)
Homoarginine (mM/L) 2.5761.09 2.9061.02 2.6461.06 2.5261.24 2.0560.78 0.002
GFR denotes glomerular filtration rate measured by iohexol clearance, BMI; body-mass index.
Data are presented as mean 6 SD and 25th, 50th (median) and 75th percentiles for skewed variables where appropriate.
P-values are for comparison across all four groups obtained from Kruskal-Wallis test, one-way ANOVA and x2 test where appropriate.
doi:10.1371/journal.pone.0063560.t001
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Interestingly, up to now all parameters investigated in the
MMKD Study showed a correlation of high concentrations with
impaired kidney function as well as progression of CKD which
points at a (direct or indirect) role of the kidney in their elimination
[24,25,29]. Homoarginine is the first parameter in the MMKD
Study, which showed not only lower concentrations at decreased
kidney function, but also a higher probability of CKD progression
at low concentrations. This is in line with the finding that
homoarginine is mainly synthesized in the kidney by transamini-
dation of lysine [6]. The formation of homoarginine in the kidney
is mediated by the l-arginine:glycine amidinotransferase (AGAT or
GATM). It has been shown that there is an organ-specific pattern
of AGAT expression with highest levels in renal tissue, which
supports a crucial role of the kidney in homoarginine metabolism
[30]. This enzyme also catalyzes an essential step of the creatine
metabolism [31], namely the conversion of arginine and glycine
into guanidinoacetate and ornithine. It is a reversible process
which depends on the concentration of co-reactants. If lysine is
sufficiently available, AGAT converts lysine together with
guanidinoacetate to form homoarginine (and glycine) [5]. Since
AGAT is able to catalyze a number of transamidination reactions,
homoarginine can also be formed from other substrates, e.g. by the
AGAT-mediated reaction of guanidinopropionic acid with orni-
thine. AGAT is mainly present in the kidney, but also in various
other organs including the liver, the pancreas and the heart. The
importance of the kidney for homoarginine synthesis is supported
by our observation of a virtually linear association between
homoarginine concentrations and GFR. In our cross-sectional
analyses, we found homoarginine concentrations lower at lower
levels of GFR. These findings are entirely consistent with genome-
wide association studies (GWAS) showing that polymorphisms of
AGAT are significantly associated with GFR [7,8].
In line with this, homoarginine is believed to derive mainly from
endogeneous synthesis rather than from nutrition: Although it
Table 2. Baseline clinical and laboratory data of the 139 patients who completed follow-up and stratified by patient groups with
and without progression of chronic kidney disease.
All patients Non-progressors Progressors
Variable (n =139) (n=83) (n=56) P-valuea
Sex: males/females, n (%) 90/49 54/29 36/20 0.93
(64.7/35.3) (65.1/34.9) (64.3/35.7)
Age (years) 46.6612.5 45.2613.0 48.6611.4 0.18
BMI (kg/m2) 25.363.6 25.063.5 25.763.8 0.22
Current smokers, n (%) 22 (15.8) 11 (13.3) 11 (19.6) 0.32
Systolic blood pressure (mmHg) 136620 135622 138617 0.32
Diastolic blood pressure (mmHg) 85612 84613 88612 0.09
Serum albumin (g/dL) 4.660.4 4.660.5 4.660.4 0.99
Proteinuria (g/24 h/1.73 m2) 1.0060.92 0.8060.93 1.3060.84 ,0.001
(0.24;0.69;1.54) (0.14;0.36;1.14) (0.63;1.10;1.85)
GFR (mL/min/1.73 m2) 62641 79641 37624 ,0.001
(34;52;87) (50;70;100) (19;33;45)
Creatinine (mmol/L) 1956118 131663 2896119 ,0.001
(105;157;253) (90;119;158) (194;281;385)
Homoarginine (mM/L) 2.5061.08 2.7161.13 2.1960.93 0.005
GFR denotes glomerular filtration rate measured by iohexol clearance, BMI; body-mass index.
Data are presented as mean 6 SD and 25th, 50th (median) and 75th percentiles for skewed variables where appropriate.
aP value for comparison between progressors and non-progressors.
doi:10.1371/journal.pone.0063560.t002
Table 3. The association of homoarginine with progression of kidney disease during the observation period using multiple Cox
proportional hazards regression models.
Model 1a Model 2a Model 3a
Variable (1 SD decrement) HR (95% CI) p HR (95% CI) p HR (95% CI) p
Homoarginine (21.1 mM/L) 1.62 (1.16–2.27) 0.005 1.56 (1.11–2.20) 0.010 1.40 (0.98–1.98) 0.06
Proteinuria (0.92 g/24 h/1.73 m2) – – 1.32 (1.05–1.67) 0.019 1.36 (1.06–1.75) 0.016
GFR (241 mL/min/1.73 m2) – – – – 4.98 (1.98–8.85) ,0.001
The hazard ratios (HR) and 95% confidence intervals (CI) were determined by univariate and multiple Cox proportional hazards regression analysis and are indicated for
each decrement of 1 standard deviation (SD). For proteinuria, hazard ratios are indicated for each increment of 1 SD.
aThe estimates in model 1 are adjusted for age and sex, those in model 2 are adjusted for age, sex and proteinuria and those in model 3 are adjusted for age, sex,
proteinuria and GFR.
doi:10.1371/journal.pone.0063560.t003
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cannot be fully excluded that uptake from the diet contributes to
normal endogenous homoarginine levels [32], diet is unlikely to
form a meaningful source of homoarginine status. Only small
amounts of homoarginine are found in lentil and similar legumes.
Noteworthy concentrations are exclusively present in two plant
species of the grass pea family Lathyrus cicera [33] and Lathyrus
sativus [34] which are not part of a usual Western diet. We are also
aware that protein-energy wasting which frequently develops in
patients with CKD might contribute to a decline in kidney
function. The correlation of homoarginine with BMI and albumin
as parameters of nutritional status, however, were only moderate.
In our additional analyses, neither BMI nor albumin were
associated with the progression of kidney disease and it is
important to note that the relationship of homoarginine with
progression was still significant after adjustments for albumin and
BMI. Our results therefore support the notion that homoarginine
concentration and its effect upon clinical outcome is not
meaningfully affected by nutrition.
Our finding of an association of homoarginine with kidney
function is furthermore in line with previous clinical studies. In the
LURIC cohort comprising patients undergoing coronary angiog-
raphy, homoarginine was significantly correlated to GFR with a
correlation coefficient of 0.23 (p,0.001). The mean homoarginine
concentration in this cohort was 2.661.1 mmol/L and patients
had a mean GFR of 81619 ml/min [35]. Of note, homoarginine
concentrations were less than half as high in patients with end-
stage renal disease requiring maintenance dialysis: patients in the
4D study had a mean homoarginine concentration of
1.260.5 mmol/l [35]. The concentrations that identified the
respective interquartile ranges in the two cohorts were meaning-
fully lower in the 4D as compared to the LURIC study (0.87–
1.4 mmol/L versus 1.85–3.1 mmol/L). The interquartile range for
homoarginine in the MMKD Study was 1.81–3.13 mmol/L,
which is close to that found in the LURIC study. Patients in the
present study had mild to moderate kidney failure and a mean
GFR of 69643 ml/min. The main explanation for the decreased
homoarginine concentrations in patients with advanced stages of
kidney disease might be due to reduced activity of AGAT (see
above). This hypothesis is supported by an experimental study by
Tofuku et al. who found a decreased renal AGAT activity in
rabbits with chronic kidney failure [36]. Similarly, plasma
concentrations of homoarginine were significantly decreased in
nephrectomized rats as compared to a sham-operated control
group [37]. Taken together, low homoarginine concentration may
therefore be an early indicator of kidney failure likely reflecting a
decreasing synthesis capacity of the kidney [5].
In a second and independent synthesis route, homoarginine can
be formed within an alternative urea cycle. Through this cycle,
homoarginine serves as a precursor of NO by increasing the
intracellular concentration of L-arginine, which is the main
substrate for NO synthase [18–21]. Homoarginine is also an
inhibitor of arginase, further increasing the bioavailability of
arginine and enhancing nitric oxide formation. Thus, homo-
arginine may increase the availability of NO and impede or
ameliorate endothelial dysfunction [9,18–22], which is crucial to
prevent progression of CKD. In previous studies, low homo-
arginine was correlated to markers of impaired endothelial
function, i.e. ICAM-1 and VCAM-1 [35]. It may therefore be
speculated whether lack of homoarginine is not only a risk marker,
but potentially a risk factor in the progression of CKD. In our
study, low homoarginine was significantly associated with disease
progression, which was independent of age, sex and proteinuria
and which was slightly attenuated when adjusted for baseline
GFR. However, adjustment for GFR could be considered as an
overadjustment since homoarginine is significantly associated with
GFR and may even mediate the effect of lower GFR on
progression of kidney disease leading hypothetically to a vicious
cycle.
The previously shown experimental effects of homoarginine on
blood pressure regulation and calcium-phosphate metabolism may
represent further pathways by which homoarginine could poten-
tially affect the course of kidney function. Previous studies found
that administration of L-homoarginine increased urinary excretion
of nitrate, the degradation product of NO, and reduced blood
pressure in salt-sensitive hypertensive rats [9]. Homoarginine is
known to be an inhibitor of bone alkaline phosphatase [14,15] and
was suggested to negatively correlate to beta-crosslaps, osteocalcin
and decrease the risk of fractures. In addition, experimental studies
showed that homoarginine increases insulin secretion and inhibits
platelet aggregation [10,11,38]. In summary, these reports support
the findings of our study and suggest mechanisms, by which
homoarginine may preserve kidney function in the reduction of
renal risk factors [10,11,14,15,18–21,38].
Strengths and Limitations of the Study
We consider it a strength of our study that GFR was not
calculated by a formula but was measured by iohexol clearance
which is considered an exact method to measure kidney function.
In this context we refrained from investigating creatinine and
cystatin C as surrogates of renal function, given that important
novel findings pointed out the non-GFR related effects of these
parameters [39].
Potential limitations of our study deserve also comments. Due to
the observational design of our study, we cannot prove causality of
the associations between homoarginine, kidney function and
kidney disease progression. Furthermore, our study is limited by
the sample size, and homoarginine measurements were not
available in all patients of the MMKD Study. The lack of material
in 38 patients out of 177 followed did not produce a particular
selection bias: these 38 patients without homoarginine measure-
ment were not different in major risk factors compared to those
with measurements available (see Table S2). Finally, since we
investigated only patients of Caucasian origin, it has to be shown
whether our findings can be confirmed in different ethnic groups.
Conclusion
We have found homoarginine concentrations directly correlated
with kidney function in patients with CKD. Furthermore, low
homoarginine concentrations were significantly associated with the
progression of kidney disease. Low homoarginine concentrations
may be an early indicator of kidney failure and potentially useful
as a marker of disease progression. Whether homoarginine
metabolism is causally relevant for kidney disease progression
deserves further studies including randomized controlled trials
with homoarginine supplementation.
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